Jump to content

Trial outcomes

PT-141 benefits: RECONNECT results

I give the replicated result weight. The size of the change still deserves a slower look.

RECONNECT endpoints

The two Phase 3 RECONNECT trials studied 1267 premenopausal women with HSDD over 24 weeks. Participants received bremelanotide 1.75 mg subcutaneously as needed or placebo. Both main endpoints were met in both trials. The integrated differences versus placebo were:

  • FSFI-desire: +0.35, P<.001.
  • FSDS-DAO item 13: −0.33, P<.001.

The first is a desire-domain score from the Female Sexual Function Index. The second concerns distress about low desire. One moves upward with improvement, the other downward. Combining them into an invented “overall improvement” number would erase the distinction that made the trial worth doing.

Effect size

The reported differences on the two scales are statistically significant and modest. Critical re-analyses have questioned their clinical meaningfulness and the outcome measures. The objection matters because relief is experienced by individuals, while these numbers summarize groups.

I grant the result its full, limited size. Calling the change trivial on everyone’s behalf would be as presumptuous as calling it transformative. Neither judgement follows from an average. I would trade a broad claim that the medicine works for a clearer account of who experiences a worthwhile change.

Separate blank-backed questionnaires and green pencils arranged beside an empty wooden chair
Illustrated study materials. The blank sheets stand for separate responses, with no invented trial data.

PT-141 for women

The approved population is premenopausal women with acquired, generalized HSDD. The diagnosis includes distress. These words restrict how far the trial result can travel.

In the 52-week open-label extension, 684 women enrolled and desire improvements were sustained. An open-label extension follows participants with everyone aware of the treatment, so its evidence about persistence has a different strength from a blinded comparison with placebo. Postmenopausal women remain outside the approval.

PT-141 for men

The earlier programme included erectile-dysfunction research. A development profile from 2004 records an intranasal programme with a completed Phase IIb ED trial and Phase III planned. The foundational paper also describes erectile activity in men with ED, alongside its animal work. These are historical findings.

Use in men remains off-label or investigational. A 2008 erectile-dysfunction salvage study later received a 2023 Expression of Concern, a formal editorial notice questioning a paper’s integrity. I would exclude that disputed finding from any confident account of benefit. The female HSDD approval cannot fill the evidential gap for men.

Benefit alongside unwanted effects

The extension’s adverse-event figures included nausea in 40.4%, flushing in 20.6% and headache in 12.0%. They were drug-related treatment-emergent events in that study. The figures describe different outcomes from the desire scales and offer no valid shortcut to a single benefit-minus-harm score.

A treatment decision needs room for both the hoped-for change and the burden of pursuing it. The safety account covers clinical exclusions as well as tolerability; the dose record stays with the documented label and research figures.